poster

Tardive Dyskinesia Across the Complexity Spectrum: From Quality of Life Improvement to Novel Treatments

Tardive dyskinesia, or TD, is a side effect of treatment with antipsychotic medications, resulting in repetitive and uncontrollable movements of the body and face. Affecting approximately...

01/19/2023

Reduction in Health Care-Related Costs After Initiation of Treatment With a Prescription Digital Therapeutic for Chronic Insomnia: Two-year Follow up Analysis of Health Care Claims Data

Abstract: Objective: This study evaluated the 2-year effectiveness of the first FDA-authorized prescription digital therapeutic (PDT) for adults with chronic insomnia that delivers eviden...

01/19/2023

Efficacy and Safety of Zuranolone in Adults With Major Depressive Disorder With and Without Use of Standard-of-Care Antidepressants at Baseline in the LANDSCAPE Clinical Development Program

Abstract: Introduction Zuranolone is a neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an oral, once-daily, ...

01/19/2023

Sustained Benefits of Zuranolone in Patients With Major Depressive Disorder: Results From the LANDSCAPE Clinical Development Program

Abstract: Introduction Many patients with major depressive disorder (MDD) experience relapse after responding to standard-of-care antidepressants. Zuranolone is a neuroactive steroid and ...

01/19/2023

AXS-05 (Dextromethorphan-Bupropion) Improves Depressive Symptoms and Functioning in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study

Abstract: Background: In STAR*D, following non-remission with an SSRI, remission rates for second line treatments were ~ 25% regardless of the switch strategy employed. Antidepressants ...

01/19/2023

Improvement in Anxiety Symptoms in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-label, Long-term Study

Abstract: Background: Innovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed. AXS-05 (dextromethorphan HBr 45 mg- bupropion HCl...

01/19/2023

Studying the Impact of Patient Treatment Experiences on Patient Hope for Major Depressive Disorder Pharmacotherapies

Abstract: Background: Individuals receiving treatment for major depressive disorder (MDD) continue to face multiple disease or treatment-related issues. A web-based survey was conducted w...

01/19/2023

Long-Term Safety and Symptom Trajectory With Aripiprazole Lauroxil in Female Patients With Schizophrenia: A Post Hoc Subgroup Analysis

Abstract: Background: Females are often underrepresented in clinical trials of antipsychotic treatment of schizophrenia. Symptom trajectory and safety outcomes in female patients who rece...

01/19/2023

Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (Dextromethorphan-Bupropion), an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double-Blind, Controlled Trials

Abstract: Background: AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorpha...

01/19/2023

Improving Patient Outcomes with the PHQ-9 in a Longitudinal Sample of Psychiatric Inpatients

Abstract: This study investigated the implementation of depression screening with the Patient Health Questionnaire (PHQ-9) in inpatient psychiatric care in a tri-state hospital group, Oce...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products